Generated by AI
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for rare diseases, with a primary emphasis on hereditary angioedema (HAE). Its commercial portfolio is centered on ORLADEYO, an oral therapy used to help prevent HAE attacks, alongside RAPIVAB, an injectable antiviral medicine used in the treatment of influenza in the United States. The company also supports a broader rare-disease pipeline built around oral small-molecule and protein-based therapeutics designed to address difficult-to-treat conditions. BioCryst Pharmaceuticals serves patients, physicians, and healthcare systems through specialty pharmaceutical products aimed at chronic disease management and acute treatment needs. Headquartered in Durham, North Carolina, BioCryst Pharmaceuticals plays a focused role in the rare-disease market by combining commercial medicines with targeted drug development expertise.
Website4505 Emperor Boulevard
Durham, NC, 27703
United States
The latest articles about BCRX.
BioCryst Pharmaceuticals (BCRX) stock is in focus after third quarter results showed revenue of US$180.29 million and net income of US$37.92 million, along with higher full year 2026 revenue guidance. Against that earnings backdrop, BioCryst Pharmaceuticals shares have been under pressure in recent months, with the 30 day share price return down 8.45% and the 90 day move down 18.02%. However, the year to date share price return is positive at 2.53% and the 3 year total shareholder return is...
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 11's posts. Generated by AI.
Summary of Mar 26's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Investors talking about BCRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.